KAILERA THERAPEUTICS INC (KLRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$16.23+3.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KLRA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue enrollment and data generation in the global Phase 3 KaiNETIC program and U.S. Phase 2b high-dose trial for ribupatide injection targeting obesity treatment.
Stated as a priority in 2 of last 2 quarters. The global Phase 3 KaiNETIC program for ribupatide injection is enrolling over 4,700 participants with data anticipated in 2028. The U.S. Phase 2b high-dose trial fully enrolled 264 participants with data expected mid-2027. Management is delivering on enrollment milestones and trial progression as planned.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
Not enough signal yet.
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Enrollment on track in global Phase 3 KaiNETIC program; Phase 2b high-dose trial fully enrolled with data expected mid-2027.”
“Initiated global Phase 3 KaiNETIC program for ribupatide injection; U.S. Phase 2b high dose trial initiated with data anticipated in 2027.”
Advance ribupatide oral formulation development with positive Phase 2 data and plan to start global Phase 3 obesity trials in first half of 2027.
Stated as a priority in 2 of last 2 quarters. Ribupatide oral formulation showed positive Phase 2 obesity trial data with mean weight loss up to 12.1% and 38.6% of participants achieving at least 15% weight loss. The IND is active with the FDA and global Phase 3 trials are planned for first half 2027. Management is delivering on clinical development milestones.
“Ribupatide oral IND active with U.S. FDA; initiation of global Phase 3 obesity trials planned for first half of 2027.”
“Reported positive topline data from Phase 2 obesity trial of ribupatide oral; plan to initiate Phase 3 global trials as early as first half 2027.”
Progress KAI-7535 through ongoing global Phase 2 obesity trial and report data from Hengrui's Phase 3 trials in obesity and type 2 diabetes.
Stated as a priority in 2 of last 2 quarters. KAI-7535 is in a global Phase 2 obesity trial with data expected in 2027. Hengrui's Phase 3 trials reported positive topline data including up to 11.1% weight loss in obesity and HbA1c reductions of 1.50% to 1.68% in T2D. Management is delivering clinical progress consistent with stated goals.
“Global Phase 2 obesity trial ongoing; positive topline data from Hengrui Phase 3 trials in obesity and T2D.”
“Initiated global Phase 2 obesity trial for KAI-7535; positive Phase 3 T2D trial data reported by Hengrui.”
Advance KAI-4729 through Phase 1 trial initiation and data generation, with plans for Phase 2 trials in obesity and metabolic dysfunction-associated steatohepatitis.
Stated as a priority in 2 of last 2 quarters. KAI-4729 Phase 1 trial initiation is on track for 2026 with data expected in 2027. Phase 1 data showed up to 16.0% mean weight loss at Week 12. Plans for Phase 2 trials in obesity and MASH are progressing. Management is delivering clinical development milestones as planned.
“On track to begin global clinical development; Phase 1 trial initiation anticipated in 2026; data expected in 2027.”
“KAI-4729 Phase 1 trial planned outside China in 2026; data expected in 2027; Hengrui advancing Phase 2 trials in China.”
Preserve cash and capital resources to support ongoing clinical development and operations through mid-2028.
Stated as a priority in 2 of last 2 quarters. Cash, cash equivalents, and marketable securities increased from $581.9 million at 2026-Q1 to $1,171.8 million at 2026-Q2, primarily due to IPO proceeds. Management expects this capital to fund operations into mid-2028, indicating delivery on financial strength maintenance.
“Cash, cash equivalents, and marketable securities of $1,171.8 million expected to fund operations into mid-2028.”
“Cash on hand including IPO proceeds expected to fund operations into mid-2028.”